黄葵胶囊联合雷公藤多苷片对比单用雷公藤多苷片治疗糖尿病肾病有效性和安全性的Meta分析

发布时间：2018-05-02 17:03

本文选题：黄葵胶囊 + 雷公藤多苷片　；参考：《中国药房》2015年33期

【摘要】：目的:系统评价黄葵胶囊联合雷公藤多苷片对比单用雷公藤多苷片治疗糖尿病肾病(DN)的有效性和安全性,以为临床治疗提供循证参考。方法:计算机检索相关期刊论文、万方数据库、中文科技期刊数据库、Cochrane图书馆、EMBase和Medline,收集黄葵胶囊联合雷公藤多苷片(试验组)对比单用雷公藤多苷片(对照组)治疗DN的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取和质量评价后,采用Rev Man 5.1统计软件进行Meta分析。结果:共纳入5项RCT,合计400例患者。Meta分析结果显示,试验组患者有效率[OR=4.10,95%CI(2.27,7.38),P0.001]、24 h尿蛋白定量值[MD=-0.54,95%CI(-0.72,-0.36),P0.001]显著高于对照组,差异均有统计学意义;丙氨酸氨基转移酶值[MD=0.14,95%CI(-1.08,1.36),P=0.82]、外周血白细胞变化值[MD=-0.31,95%CI(-0.64,0.03),P=0.07]与对照组相比,差异均无统计学意义。结论:黄葵胶囊联合雷公藤多苷片治疗DN的疗效优于单用雷公藤多苷片,且安全性相当。受纳入研究方法学质量限制,该结论有待更多设计严格、长期随访的大样本RCT加以验证。
[Abstract]:Objective: to evaluate the efficacy and safety of Huangkui capsule combined with Tripterygium wilfordii polyglycoside tablets in the treatment of diabetic nephropathy. Methods: the full text database of Chinese periodicals and the database of Wanfang were searched by computer. The database of Chinese scientific and technological journals, EMBase and Medline, were collected from the Cochrane Library of Huangkui capsule combined with Tripterygium wilfordii polyglycoside tablets (trial group), and compared with the randomized controlled trial of Tripterygium wilfordii polyglycoside (control group) in the treatment of DN. After the data extraction and quality evaluation of the bed study, Meta analysis was carried out with Rev Man 5.1 statistical software. Results: a total of 400 RCTs were included. The results of Meta-analysis showed that the effective rate of patients in the trial group was significantly higher than that in the control group. The effective rate of the patients in the trial group [OR4.1095] was significantly higher than that in the control group (P 0.001), and the 24 h urinary protein quantitative value was significantly higher than that in the control group. The value of alanine aminotransferase [MDT 0.1495] CI-1.08 ~ 1.36 / P0. 82, and the change of peripheral blood leukocytes [MD-0.31 / 95] were not significantly different from those of the control group. Conclusion: Huangkui capsule combined with tripterygium wilfordii polyglycoside tablet is superior to tripterygium wilfordii polyglycoside tablet in the treatment of DN. Limited by the quality of methodology included in the study, this conclusion needs to be verified by more well-designed, long-term follow-up large sample RCT.
【作者单位】：三门峡市中心医院药剂科;
【分类号】：R587.2;R692.9

【参考文献】